Skip to main content

Table 4 Univariate and multivariate analyses of ORR and DCR according to clinical and treatment characteristics

From: Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Characteristics ORR, No. (%) *p-value gOR (95% CI), p-value DCR, No. (%) *p-value gOR (95% CI), p-value
EGFR mutation subtype, No. (%)
Exon 19 deletion 52 (76.5) 0.265 2.27 (0.47–11.01), 0.309a 64 (94.1) 0.263 2.72 (0.41–18.24), 0.302a
Exon 21 L858R point mutation 6 (54.5)   0.40 (0.03–5.21), 0.485b 9 (81.8)   2.28 (0.31–16.62), 0.420b
 Rare and complex mutation 5 (83.3)    6 (100)   
Baseline symptomatic brain metastases, No. (%)
 No 49 (81.7) 0.014 4.51 (1.45–14.00), 0.009# 57 (95.0) 0.251 3.0 (0.55–16.38), 0.205#
 Yes 14 (56.0)    22 (88.0)   
ECOG performance status, No. (%)
 0–1 49 (71.0) 0.175 0.27 (0.05–1.44), 0.125# 64 (92.8) 0.889 0.79 (0.08–8.76), 0.835#
 2–4 14 (87.5)    15 (93.8)   
Abnormal organ function, No. (%)
 No 53 (75.7) 0.468 1.27 (0.28–5.81), 0.755# 64 (91.4) 0.585 0.57 (0.07–4.97), 0.616 #
 Yes 10 (66.7)    15 (100)   
Afatinib dose adjustment, No. (%)
 Dose reduced 23 (88.5) 0.084 5.53 (1.32–23.24), 0.019c 25 (96.2) 0.729 3.22 (0.29–35.40), 0.339c
 Dose increased 8 (80.0)   2.13 (0.36–12.57), 0.404d 9 (90.0)   1.30 (0.11–15.02), 0.835d
 Starting dose maintained 32 (65.3)    45 (91.8)   
Optimal afatinib dose, No. (%)
 Less than 40 mg once daily 40 (78.4) 0.156 2.03 (0.59–6.94), 0.259e 47 (92.2) 0.836 0.88; 0.13–6.13, 0.895e
 40 mg once daily 19 (63.3)    28 (29.3)   
 50 mg once daily 4 (100)f    4 (100)f   
  1. Abbreviations: ORR objective response rate, DCR disease control rate, OR odd ratio, 95% CI 95% confidence interval, EGFR epidermal growth factor receptor, ECOG Eastern Cooperative Oncology Group
  2. *p-value of Chi-square test
  3. #second parameter was the reference group
  4. aexon 19 deletion versus exon 21 L858R point mutation; bexon 19 deletion versus rare and complex mutations
  5. cafatinib dose reduced versus starting dose maintained; dafatinib dose increased versus starting dose maintained
  6. eafatinib less than 40 mg once daily versus 40 mg once daily
  7. fafatinib dose 50 mg once daily not compared because of the small number of patients
  8. gmultivariate analysis with cox regression